New CAR-T therapy targets BAFF-R to fight resistant lymphoma
NCT ID NCT07259070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment called BAFF-R CAR-T for people with B-cell lymphoma that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to find and attack cancer cells carrying a protein called BAFF-R. The study will enroll 20 participants to check safety, find the best dose, and see if the therapy can shrink tumors or slow the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can a cancer biopsy predict who responds to a new immunotherapy?
- Can a Zinc-Based compound fight cancer?
- Can a new drug combo outsmart resistant lymphomas?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?